U.S., May 5 -- ClinicalTrials.gov registry received information related to the study (NCT07564232) titled 'Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma' on April 27.
Brief Summary: There are 2 parts to this clinical research study: Part 1 (Dose Escalation) and Part 2 (Dose Expansion).
The goal of Part 1 is to find the recommended dose of LNK001 in patients with advanced or metastatic ccRCC.
The goal of Part 2 is to learn if the recommended dose of LNK001 found in Part 1 can help to control the disease.
Study Start Date: Oct. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Clear Cell Renal Cell Carcinoma
Intervention:
DRUG: Cyclophosphamide
Given by IV
DRUG: Fludarabine
Given by IV
DRUG: LNK00...